136 related articles for article (PubMed ID: 31682006)
1. Primary therapy and survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma: a population-based analysis in the Netherlands, 1993-2016.
Posthuma HLA; Zijlstra JM; Visser O; Lugtenburg PJ; Kersten MJ; Dinmohamed AG
Br J Haematol; 2020 Apr; 189(1):117-121. PubMed ID: 31682006
[TBL] [Abstract][Full Text] [Related]
2. A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma.
Strobbe L; Valke LL; Diets IJ; van den Brand M; Aben K; Raemaekers JM; Hebeda KM; van Krieken JH
Ann Hematol; 2016 Feb; 95(3):417-23. PubMed ID: 26732883
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
Gerber NK; Atoria CL; Elkin EB; Yahalom J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
[TBL] [Abstract][Full Text] [Related]
4. Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.
Lazarovici J; Dartigues P; Brice P; Obéric L; Gaillard I; Hunault-Berger M; Broussais-Guillaumot F; Gyan E; Bologna S; Nicolas-Virelizier E; Touati M; Casasnovas O; Delarue R; Orsini-Piocelle F; Stamatoullas A; Gabarre J; Fornecker LM; Gastinne T; Peyrade F; Roland V; Bachy E; André M; Mounier N; Fermé C
Haematologica; 2015 Dec; 100(12):1579-86. PubMed ID: 26430172
[TBL] [Abstract][Full Text] [Related]
5. Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres.
Illés A; Simon Z; Tóth E; Rosta A; Miltényi Z; Molnár Z
Pathol Oncol Res; 2008 Dec; 14(4):411-21. PubMed ID: 18431694
[TBL] [Abstract][Full Text] [Related]
6. Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base.
Olszewski AJ; Shrestha R; Cook NM
Cancer; 2015 Oct; 121(19):3472-80. PubMed ID: 26149294
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Fuchs M; Sasse S; Baues C; Böll B; von Tresckow B; Diehl V; Borchmann P; Engert A
J Clin Oncol; 2020 Mar; 38(7):698-705. PubMed ID: 31626571
[TBL] [Abstract][Full Text] [Related]
8. Improved survival for adolescents and young adults with Hodgkin lymphoma and continued high survival for children in the Netherlands: a population-based study during 1990-2015.
Reedijk AMJ; Zijtregtop EAM; Coebergh JWW; Meyer-Wentrup FAG; Hebeda KM; Zwaan CM; Janssens GOR; Pieters R; Plattel WJ; Dinmohamed AG; Zijlstra JM; Kremer LCM; Lugtenburg PJ; Beishuizen A; Karim-Kos HE
Br J Haematol; 2020 Jun; 189(6):1093-1106. PubMed ID: 32030738
[TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma.
Akhtar S; Elhassan TAM; Edesa W; Rauf MS; Zahir MN; Maghfoor I
Ann Hematol; 2016 Jan; 95(1):49-54. PubMed ID: 26467917
[TBL] [Abstract][Full Text] [Related]
10. Nodular lymphocyte predominant Hodgkin lymphoma in USA between 2000 and 2014: an updated analysis based on the SEER data.
Shivarov V; Ivanova M
Br J Haematol; 2018 Sep; 182(5):727-730. PubMed ID: 28737250
[No Abstract] [Full Text] [Related]
11. Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989-2017.
Driessen J; Visser O; Zijlstra JM; Lugtenburg PJ; Plattel WJ; Kersten MJ; Dinmohamed AG
Leukemia; 2021 Feb; 35(2):494-505. PubMed ID: 32461630
[TBL] [Abstract][Full Text] [Related]
12. Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry.
Molin D; Linderoth J; Wahlin BE
Br J Haematol; 2017 May; 177(3):449-456. PubMed ID: 28233899
[TBL] [Abstract][Full Text] [Related]
13. Incidence, management, and outcome of high-grade transformation of nodular lymphocyte predominant Hodgkin lymphoma: long-term outcomes from a 30-year experience.
Eyre TA; Gatter K; Collins GP; Hall GW; Watson C; Hatton CS
Am J Hematol; 2015 Jun; 90(6):E103-10. PubMed ID: 25715900
[TBL] [Abstract][Full Text] [Related]
14. Unfavorable presentation but comparable outcome: Presentation and outcome of children with nodular lymphocyte predominant Hodgkin lymphoma from India.
Prasad M; Narula G; Chinnaswamy G; Arora B; Shet T; Panjwani P; Sengar M; Laskar S; Khanna N; Banavali S
Pediatr Blood Cancer; 2018 Oct; 65(10):e27288. PubMed ID: 29893471
[TBL] [Abstract][Full Text] [Related]
15. Disparate survival and risk of secondary non-Hodgkin lymphoma in histologic subtypes of Hodgkin lymphoma: a population-based study.
Ali S; Olszewski AJ
Leuk Lymphoma; 2014 Jul; 55(7):1570-7. PubMed ID: 24067135
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Fuchs M; von Tresckow B; Böll B; Behringer K; Diehl V; Eich HT; Borchmann P; Engert A
J Clin Oncol; 2015 Sep; 33(26):2857-62. PubMed ID: 26240235
[TBL] [Abstract][Full Text] [Related]
17. Transformation and outcome of nodular lymphocyte predominant Hodgkin lymphoma: a Finnish Nationwide population-based study.
Kalashnikov I; Tanskanen T; Pitkäniemi J; Malila N; Jyrkkiö S; Leppä S
Blood Cancer J; 2021 Dec; 11(12):203. PubMed ID: 34923571
[TBL] [Abstract][Full Text] [Related]
18. Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up.
Liu L; Giusti F; Schaapveld M; Aleman B; Lugtenburg P; Meijnders P; Hutchings M; Lemmens V; Bogaerts J; Visser O
Br J Haematol; 2017 Jan; 176(1):65-75. PubMed ID: 27766636
[TBL] [Abstract][Full Text] [Related]
19. Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network.
Farrell K; McKay P; Leach M
Leuk Lymphoma; 2011 Oct; 52(10):1920-8. PubMed ID: 21663507
[TBL] [Abstract][Full Text] [Related]
20. High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.
Akhtar S; Montoto S; Boumendil A; Finel H; Masszi T; Jindra P; Nemet D; Fuhrmann S; Beguin Y; Castagna L; Ferrara F; Capria S; Malladi R; Moraleda JM; Bloor A; Ghesquières H; Meissner J; Sureda A; Dreger P
Am J Hematol; 2018 Jan; 93(1):40-46. PubMed ID: 28971503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
